Characterization of the spectrum of trivalent VAV1-mutation-driven tumours using a gene-edited mouse model.


Journal

Molecular oncology
ISSN: 1878-0261
Titre abrégé: Mol Oncol
Pays: United States
ID NLM: 101308230

Informations de publication

Date de publication:
10 2022
Historique:
revised: 07 07 2022
received: 23 03 2022
accepted: 26 07 2022
pubmed: 28 7 2022
medline: 7 10 2022
entrez: 27 7 2022
Statut: ppublish

Résumé

Mutations in the VAV1 guanine nucleotide exchange factor 1 have been recently found in peripheral T cell lymphoma and nonsmall-cell lung cancer (NSCLC). To understand their pathogenic potential, we generated a gene-edited mouse model that expresses a VAV1 mutant protein that recapitulates the signalling alterations present in the VAV1 mutant subclass most frequently found in tumours. We could not detect any overt tumourigenic process in those mice. However, the concurrent elimination of the Trp53 tumour suppressor gene in them drives T cell lymphomagenesis. This process represents an exacerbation of the normal functions that wild-type VAV1 plays in follicular helper T cells. We also found that, in combination with the Kras oncogene, the VAV1 mutant version favours progression of NSCLC. These data indicate that VAV1 mutations play critical, although highly cell-type-specific, roles in tumourigenesis. They also indicate that such functions are contingent on the mutational landscape of the tumours involved.

Identifiants

pubmed: 35895495
doi: 10.1002/1878-0261.13295
pmc: PMC9533688
doi:

Substances chimiques

Mutant Proteins 0
Proto-Oncogene Proteins c-vav 0
Vav1 protein, mouse 0
Proto-Oncogene Proteins p21(ras) EC 3.6.5.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3533-3553

Informations de copyright

© 2022 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.

Références

Immunity. 2014 Oct 16;41(4):529-42
pubmed: 25367570
Cell Rep. 2019 Aug 13;28(7):1758-1772.e4
pubmed: 31412245
Blood. 2016 Sep 1;128(9):1234-45
pubmed: 27297792
Blood. 2019 Apr 11;133(15):1664-1676
pubmed: 30782609
Cancer Cell. 2015 Apr 13;27(4):516-32
pubmed: 25873174
Cancer Res. 2007 Nov 15;67(22):10703-10
pubmed: 18006812
Nat Rev Immunol. 2010 Sep;10(9):645-56
pubmed: 20725108
Sci Signal. 2014 Apr 15;7(321):ra35
pubmed: 24736456
Cancer Cell. 2017 Nov 13;32(5):608-623.e9
pubmed: 29136506
Cancer Cell. 2018 Feb 12;33(2):259-273.e7
pubmed: 29398449
Mol Cell Biol. 1995 Aug;15(8):4337-46
pubmed: 7623828
Biology (Basel). 2021 Sep 08;10(9):
pubmed: 34571765
J Clin Exp Hematop. 2020 Sep 25;60(3):66-72
pubmed: 32779615
Nat Genet. 2014 Apr;46(4):371-5
pubmed: 24584070
Nat Rev Immunol. 2002 Jul;2(7):476-86
pubmed: 12094222
Proc Natl Acad Sci U S A. 2017 Jan 24;114(4):764-769
pubmed: 28062691
Oncotarget. 2015 Oct 6;6(30):28731-42
pubmed: 26353933
Development. 2016 Feb 1;143(3):437-48
pubmed: 26718008
EMBO J. 2021 Nov 15;40(22):e108125
pubmed: 34617326
J Biol Chem. 2000 Jan 21;275(3):2185-90
pubmed: 10636924
Nat Rev Cancer. 2020 Jun;20(6):323-342
pubmed: 32249838
Blood. 2020 Dec 24;136(26):3018-3032
pubmed: 32992343
J Exp Med. 2015 Apr 6;212(4):539-53
pubmed: 25824819
Small GTPases. 2020 Jul;11(4):233-239
pubmed: 29313423
Mol Cell Biol. 2000 Mar;20(5):1678-91
pubmed: 10669745
PLoS Biol. 2013 Jul;11(7):e1001615
pubmed: 23935450
Blood. 2017 Sep 21;130(12):1430-1440
pubmed: 28694326
Nat Rev Cancer. 2006 May;6(5):347-59
pubmed: 16612405
Cells. 2019 May 16;8(5):
pubmed: 31100928
Immunity. 1997 Oct;7(4):451-60
pubmed: 9354466
Cancer Cell. 2019 Sep 16;36(3):268-287.e10
pubmed: 31447347
Nat Genet. 2016 Jun;48(6):607-16
pubmed: 27158780
J Clin Invest. 2017 Aug 1;127(8):2998-3012
pubmed: 28691928
Front Immunol. 2019 Mar 29;10:606
pubmed: 30984183
Nat Protoc. 2009;4(7):1064-72
pubmed: 19561589
Blood Adv. 2021 Dec 28;5(24):5588-5598
pubmed: 34592752
Nat Med. 2006 Jul;12(7):841-5
pubmed: 16767097
Nat Commun. 2021 Jun 17;12(1):3705
pubmed: 34140493
Cell. 2000 Sep 1;102(5):625-33
pubmed: 11007481
Nat Cancer. 2021 Jan;2(1):98-113
pubmed: 33928261
J Pathol. 2009 Sep;219(1):25-34
pubmed: 19533802
J Clin Invest. 2013 Oct;123(10):4449-63
pubmed: 24091327
Life Sci Alliance. 2020 Apr 10;3(5):
pubmed: 32277014
J Immunol. 2016 Mar 1;196(5):2015-9
pubmed: 26851216
Nat Commun. 2020 Sep 22;11(1):4788
pubmed: 32963234
Blood. 2007 Jun 1;109(11):4952-63
pubmed: 17284527
Blood. 2014 Dec 11;124(25):3719-29
pubmed: 25331115
EMBO J. 1989 Aug;8(8):2283-90
pubmed: 2477241
Curr Opin Cell Biol. 2018 Dec;55:1-7
pubmed: 30006050
Cancer Cell. 2005 Jan;7(1):39-49
pubmed: 15652748
Cell. 2012 Sep 14;150(6):1107-20
pubmed: 22980975
Small GTPases. 2014;5(2):9
pubmed: 25483299
Leukemia. 2020 Oct;34(10):2592-2606
pubmed: 32704161
Cell Signal. 2022 Sep;97:110395
pubmed: 35752351
Genes Dev. 2001 Dec 15;15(24):3243-8
pubmed: 11751630
Nature. 1997 Jan 9;385(6612):169-72
pubmed: 8990121
Nat Genet. 2005 Jul;37(7):718-26
pubmed: 15924142
Nat Genet. 2015 Nov;47(11):1304-15
pubmed: 26437031
Cell Growth Differ. 1993 Apr;4(4):297-308
pubmed: 8494792
J Pathol. 2003 Apr;199(4):526-33
pubmed: 12635144
Blood. 2016 Sep 15;128(11):1490-502
pubmed: 27369867
Oncogenesis. 2020 Aug 14;9(8):73
pubmed: 32796826

Auteurs

Javier Robles-Valero (J)

Molecular Mechanisms of Cancer Program, Centro de Investigación del Cáncer, CSIC-University of Salamanca, Spain.
Instituto de Biología Molecular y Celular del Cáncer, CSIC-University of Salamanca, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), CSIC-University of Salamanca, Spain.

Lucía Fernández-Nevado (L)

Molecular Mechanisms of Cancer Program, Centro de Investigación del Cáncer, CSIC-University of Salamanca, Spain.
Instituto de Biología Molecular y Celular del Cáncer, CSIC-University of Salamanca, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), CSIC-University of Salamanca, Spain.

Myriam Cuadrado (M)

Molecular Mechanisms of Cancer Program, Centro de Investigación del Cáncer, CSIC-University of Salamanca, Spain.
Instituto de Biología Molecular y Celular del Cáncer, CSIC-University of Salamanca, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), CSIC-University of Salamanca, Spain.

Luis Francisco Lorenzo-Martín (LF)

Molecular Mechanisms of Cancer Program, Centro de Investigación del Cáncer, CSIC-University of Salamanca, Spain.
Instituto de Biología Molecular y Celular del Cáncer, CSIC-University of Salamanca, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), CSIC-University of Salamanca, Spain.

Isabel Fernández-Pisonero (I)

Molecular Mechanisms of Cancer Program, Centro de Investigación del Cáncer, CSIC-University of Salamanca, Spain.
Instituto de Biología Molecular y Celular del Cáncer, CSIC-University of Salamanca, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), CSIC-University of Salamanca, Spain.

Antonio Abad (A)

Molecular Mechanisms of Cancer Program, Centro de Investigación del Cáncer, CSIC-University of Salamanca, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), CSIC-University of Salamanca, Spain.

Esther Redín (E)

Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), CSIC-University of Salamanca, Spain.
Solid Tumors Program, Center of Applied Medical Research, University of Navarra, Pamplona, Spain.

Luis Montuenga (L)

Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), CSIC-University of Salamanca, Spain.
Solid Tumors Program, Center of Applied Medical Research, University of Navarra, Pamplona, Spain.

Dionisio Martín-Zanca (D)

Instituto de Biología Funcional y Genómica, CSIC-University of Salamanca, Spain.

Anna Bigas (A)

Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), CSIC-University of Salamanca, Spain.
Institut Hospital del Mar d'Investigacions Médiques, Barcelona, Spain.

Moisés Mallo (M)

Gulbenkian Institute, Oeiras, Portugal.

Mercedes Dosil (M)

Molecular Mechanisms of Cancer Program, Centro de Investigación del Cáncer, CSIC-University of Salamanca, Spain.
Instituto de Biología Molecular y Celular del Cáncer, CSIC-University of Salamanca, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), CSIC-University of Salamanca, Spain.

Xosé R Bustelo (XR)

Molecular Mechanisms of Cancer Program, Centro de Investigación del Cáncer, CSIC-University of Salamanca, Spain.
Instituto de Biología Molecular y Celular del Cáncer, CSIC-University of Salamanca, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), CSIC-University of Salamanca, Spain.

Articles similaires

Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH